[TechWorld News | Reporter Jisung Park]
REV-MED (CEO Edward BG Shin) announced its participation in TNOACON 2025, held in India from February 7 to 9, where research utilizing its TriCell PRP technology was presented, showcasing the excellence of Korean biomedical innovation on the global stage.
TNOACON is the annual conference hosted by the Tamil Nadu Orthopaedic Association, serving as a key platform for advancing orthopedic practices and fostering collaboration among global experts. During the conference, Dr. Elizabeth Vinod led a session on the orthopedic applications of Platelet-Rich Plasma (PRP), highlighting the therapeutic potential of biological products in regenerative treatments.
In particular, REV-MED’s TriCell PRP product received significant attention. The research presented emphasized its double-spin separation system, which efficiently concentrates platelet-rich plasma, resulting in clearly superior clinical outcomes. Developed with fully domestic technology, TriCell PRP allows high-efficiency and safe concentration of autologous blood and bone marrow with minimal manipulation.
Globally, platelet concentration technology is gaining traction in orthopedic treatments, especially in tissue regeneration and wound healing, making PRP kits increasingly relevant. Amid this trend, TriCell PRP stands out as an innovative, Korea-based product making its mark on the international market.
A REV-MED representative commented,
“This presentation at TNOACON 2025 has been a pivotal opportunity to showcase our advanced technologies and product excellence globally. We will continue to focus on R&D to strengthen our competitiveness and solidify our position in the global biomedical industry.”
Meanwhile, in December 2024, the use of intra-articular PRP injection for early-stage knee osteoarthritis was officially recognized as a new medical technology by the Korean Ministry of Health and Welfare.
Source: TechWorld News
[TechWorld News | Reporter Jisung Park]
REV-MED (CEO Edward BG Shin) announced its participation in TNOACON 2025, held in India from February 7 to 9, where research utilizing its TriCell PRP technology was presented, showcasing the excellence of Korean biomedical innovation on the global stage.
TNOACON is the annual conference hosted by the Tamil Nadu Orthopaedic Association, serving as a key platform for advancing orthopedic practices and fostering collaboration among global experts. During the conference, Dr. Elizabeth Vinod led a session on the orthopedic applications of Platelet-Rich Plasma (PRP), highlighting the therapeutic potential of biological products in regenerative treatments.
In particular, REV-MED’s TriCell PRP product received significant attention. The research presented emphasized its double-spin separation system, which efficiently concentrates platelet-rich plasma, resulting in clearly superior clinical outcomes. Developed with fully domestic technology, TriCell PRP allows high-efficiency and safe concentration of autologous blood and bone marrow with minimal manipulation.
Globally, platelet concentration technology is gaining traction in orthopedic treatments, especially in tissue regeneration and wound healing, making PRP kits increasingly relevant. Amid this trend, TriCell PRP stands out as an innovative, Korea-based product making its mark on the international market.
A REV-MED representative commented,
“This presentation at TNOACON 2025 has been a pivotal opportunity to showcase our advanced technologies and product excellence globally. We will continue to focus on R&D to strengthen our competitiveness and solidify our position in the global biomedical industry.”
Meanwhile, in December 2024, the use of intra-articular PRP injection for early-stage knee osteoarthritis was officially recognized as a new medical technology by the Korean Ministry of Health and Welfare.
Source: TechWorld News